Brent K. Hollenbeck, MD, MS
Photo: Brent K. Hollenbeck

Email:

Phone:

None available.

Resources:

Elected 2020

Dr. Brent K. Hollenbeck is a urologic oncologist and Chair of Urology at the Massachusetts General Hospital. A graduate of Indiana University School of Medicine, he completed his residency in urology and fellowship training in oncology at the University of Michigan. Dr. Hollenbeck joined the faculty at Michigan in 2005 and subsequently served in multiple leadership roles during his tenure, including Director of Division of Health Services Research, Associate Chair for Research and Vice Chair. In 2023, he was recruited by the Massachusetts General Hospital to serve as Chair of Urology. His vision for MGH Urology is to be widely recognized as the premier Department, renowned as the incubator for developing leaders in the field and for discovery aimed at eliminating suffering from urological diseases.

Dr. Hollenbeck’s clinical practice is uniformly focused on caring for men with prostate cancer. The genesis of this focus was borne out of patient demand and capped only by his commitments to extramurally funded research. Over nearly two decades, he built one of the largest prostate cancer surgical practices in the state of Michigan, the epicenter of robotic surgery in the early 2000s. He has acquired a strong national and international reputation as one of the premier surgeon-scientists focused on prostate cancer.

As Chair of MGH Urology, Dr. Hollenbeck is committed to being a force-multiplier in the field by catalyzing the scientific and professional trajectories of colleagues and learners. His lab has been continuously funded since 2007 and has served as a substrate for learners to pursue their own avenues of discovery. He is supported by R01s from the NCI, AHRQ and NIA and a Research Scholar Grant from the American Cancer Society. Dr. Hollenbeck has served or serves as primary research mentor for 4 predoctoral students and 22 postdoctoral fellows and faculty. While measures of academic success, including extramural funding and scholarship, are tangible and imperative, they are a byproduct of his most important contribution of inspiring others to sustain impactful careers in science and cancer-related research. Among his mentees, 10 have successfully competed for career development awards and 8 have secured independent (R01 or similar) funding. Currently, 7 of his mentees serve as PI of 13 active R01s and one research-focused training award.